Intelligent Bio Solutions (INBS) announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical industries. The Company’s total number of active accounts has surpassed 450, with 35 new accounts added in fiscal Q3 alone. INBS’ Intelligent Fingerprinting Drug Screening System, which detects recent drug use in under ten minutes through fingerprint sweat analysis, continues to gain traction for its speed, portability, and ease of use. This latest growth aligns with INBS’ strategic localization and international expansion plans, targeting high-demand markets
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions Reports Strong Q3 2025 Results
- Intelligent Bio Solutions reports Q3 EPS (44c) vs ($1.43) last year
- Intelligent Bio Solutions announces launch of three new localized websites
- Intelligent Bio Solutions integrates Latin American Spanish into IFDSS
- Intelligent Bio integrate Arabic as 2nd international language to IFDS system